financetom
Business
financetom
/
Business
/
Extra Space Storage Shares Are Down As Weak Demand, Low Housing Churn Clouds Future
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Extra Space Storage Shares Are Down As Weak Demand, Low Housing Churn Clouds Future
Aug 5, 2024 12:17 PM

Extra Space Storage Inc. shares are trading lower today. Bank of America Securities analyst Joshua Dennerlei downgraded the stock to Underperform from Neutral and lowered the price target to $155 from $172.

Last week, the company reported sales of $697.1 million, missing the street view of $728.8 million.

Second-quarter funds from operations (FFO) came in at $2.06, surpassing the estimate of $2.00.

The company expects core FFO of $7.95-$8.15 for fiscal 2024.

The analyst expects declining storage demand prospects through 2025, weaker demand in markets like Florida, worsened by EXR's increased exposure from the LSI merger, and limited pricing power with new customers.

Notably, move-in rents dropped 8% year-over-year in Q2, with July rates falling 12% as new customers stayed price-sensitive, writes the analyst.

Dennerlei adds that despite earlier hopes for summer improvements, peak leasing has passed, and visibility into 2025 remains unclear, potentially due to low housing churn.

The analyst revised the core FFO estimates to $8.07 for 2025 (from $8.57) and $8.26 for 2026 (previously $8.94). These are 4.1% below the Street's 2025 estimate and 5.8% below the 2026 estimate.

Also, the analyst forecasts 2025 SS NOI growth of -1.1% vs. the Street's consensus of 1.6%.

Investors can gain exposure to the stock via iShares Residential and Multisector Real Estate ETF and Principal Exchange-Traded Funds Principal Real Estate Active Opportunities ETF .

Price Action: EXR shares are down 3.41% at $159.33 at the last check Monday.

Now Read:

5 ETFs That Strengthen Your Portfolio During Stock Turmoil

Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved